However, there is still no study assessing the efficacy-predictive and prognostic abilities of PIV and PILE at baseline in ES-SCLC patients receiving anti-PD-1/PD-L1 inhibitor combined with chemotherapy. This evidence concerns the gene PDCD1 and small cell lung carcinoma.